CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Baricitinib 4 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02340104
NCT02340104Phase 1Completed
CompareCT.gov

An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method

Eli Lilly and Company·interventional·Posted Jan 16, 2015·Updated Jun 1, 2017

In Brief

A Phase 1 clinical trial evaluating Baricitinib and [^13C4D3^15N]-baricitinib for Healthy Volunteers. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 16, 2015
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.5 years ago

Interventions

Baricitinibdrug

4 milligrams (mg) administered orally

[^13C4D3^15N]-baricitinibdrug

4 micrograms (μg) administered intravenously (IV)